This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): ceftazidime for injection
Description: Fortaz (Ceftazidime) is generally considered a third generation cephalosporin antibiotic, but its antibacterial properties are somewhat atypical of this group. Third generation cephalosporins have greater Gram-(-) activity than first or second generation cephalosporins. Compared to other third generation cephalosporins, Fortaz exhibits greater activity against Pseudomonas, but signficantly poorer activity against Gram-(+) pathogens.
GlaxoSmithKline and Covis
In December 2011, Covis Pharma Sarl announced an agreement with GlaxoSmithKline to acquire full commercial rights for Fortaz (ceftazidime), Zinacef (cefuroxime), Lanoxin (digoxin), Parnate (tranylcypromine sulfate), and Zantac Injection (ranitidine hydrochloride) in the United States and Puerto Rico. GlaxoSmithKline will retain the existing rights for these products in countries outside the United States. Terms of the agreement have not been disclosed. GSK will manufacture and supply Fortaz Injection, Zinacef Injection, Parnate, and Zantac Injection to Covis. Lanoxin Tablets and Injection, Fortaz Frozen, Zinacef Frozen and Zantac Injection Premixed will continue to be manufactured and supplied by current third-party suppliers.
Covis and Concordia
In March 2015, Concordia Healthcare announced it has entered into a definitive asset purchase agreement to acquire substantially all of the commercial assets of privately held Covis...See full deal structure in Biomedtracker
Partners: GlaxoSmithKline plc
Pink Sheet Glaxo's Ceptaz (ceftazidime)
Additional information available to subscribers only: